# VOR catalysts: Vor Biopharma Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/vor/catalysts

> Vor Biopharma Inc. (VOR) has 4 upcoming catalysts. The next is the APRIL (telitacicept) primary completion, March 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Vor Biopharma Inc. |
| Ticker | VOR (Nasdaq) |
| SEC CIK | 1817229 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/vor |

## Cash runway

Cash $481.6M as of 2026-09-30; quarterly burn $32.7M; about 44.1 months of runway at that rate (XBRL company facts, accession 0001193125-26-439905).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2024 | [VBP301 trial start](https://sec-api.dev/pdufa/vbp301) | VOR |  | completed | "In January 2024, we dosed the first patient with VCAR33 in VBP301 and are continuing to dose patients in this study." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1817229/000095017025042623/vor-20241231.htm)) |
| March 2027 | [APRIL (telitacicept) primary completion](https://sec-api.dev/pdufa/telitacicept) | VOR | Generalized Myasthenia Gravis | scheduled | "NCT06456580 (A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Vor Biopharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06456580)) |
| Mar to Jun 2027 | [APRIL (telitacicept) topline data readout](https://sec-api.dev/pdufa/telitacicept) | VOR | Generalized Myasthenia Gravis | scheduled | "NCT06456580 (A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Vor Biopharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06456580)) |
| December 2028 | [APRIL (telitacicept) primary completion](https://sec-api.dev/pdufa/telitacicept) | VOR | Primary Sjogren's Disease | scheduled | "NCT07404865 (Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Vor Biopharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07404865)) |
| Dec 2028 to Mar 2029 | [APRIL (telitacicept) topline data readout](https://sec-api.dev/pdufa/telitacicept) | VOR | Primary Sjogren's Disease | scheduled | "NCT07404865 (Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Vor Biopharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07404865)) |

## Drugs

- [APRIL (telitacicept)](https://sec-api.dev/pdufa/telitacicept): Generalized Myasthenia Gravis, Primary Sjogren's Disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/vor/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VOR catalysts: Vor Biopharma Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/vor/catalysts

```bibtex
@misc{secapidev_companies_vor_catalysts_20261116,
  title        = {VOR catalysts: Vor Biopharma Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/vor/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_vor_catalysts_20261116","title":"VOR catalysts: Vor Biopharma Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/vor/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
